ES2655911T3 - Compuestos de tetraciclina sustituidos con C7-fluoro - Google Patents

Compuestos de tetraciclina sustituidos con C7-fluoro Download PDF

Info

Publication number
ES2655911T3
ES2655911T3 ES15180611.4T ES15180611T ES2655911T3 ES 2655911 T3 ES2655911 T3 ES 2655911T3 ES 15180611 T ES15180611 T ES 15180611T ES 2655911 T3 ES2655911 T3 ES 2655911T3
Authority
ES
Spain
Prior art keywords
alkyl
alkoxy
independently selected
halo
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15180611.4T
Other languages
English (en)
Inventor
Robert B. Zahler
Roger B. Clark
Diana Katharine Hunt
Louis Plamondon
Xiao-Yi Xiao
Jingye Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tetraphase Pharmaceuticals Inc
Original Assignee
Tetraphase Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41110902&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2655911(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tetraphase Pharmaceuticals Inc filed Critical Tetraphase Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2655911T3 publication Critical patent/ES2655911T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C07C237/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
    • C07C239/08—Hydroxylamino compounds or their ethers or esters
    • C07C239/20—Hydroxylamino compounds or their ethers or esters having oxygen atoms of hydroxylamino groups etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Un compuesto representado por la Formula Estructural (II):**Fórmula** o una sal farmaceuticamente aceptable del mismo, en la que: X esta seleccionado entre hidrogeno, -alquilo (C1-C7), carbociclilo, arilo y heteroarilo; cada uno de R1 y R2 estan seleccionados independientemente entre hidrogeno, alquilo (C1-C7), cicloalquil (C3- C6)- alquilo (C1-C4), alcoxi (C1-C7)-alquilo (C1-C4), cicloalcoxi (C3-C6)-alquilo (C1-C4), cicloalquilo (C3-C6), arilo, arilalquilo (C1-C4), ariloxialquilo (C1-C4), ariltioalquilo (C1-C4), arilsufinil-alquilo (C1-C4), arilsulfonilalquilo (C1-C4) y - O-alquilo (C1-C7), o R1 y R2, tomados junto con el atomo de nitrogeno al que estan enlazados, forman un heteroarilo monociclico o biciclico, o un heterociclo monociclico, condensado biciclico, puenteado biciclico o espiro biciclico, en donde el heteroarilo o el heterociclo contienen opcionalmente uno o dos heteroatomos adicionales seleccionados independientemente entre N, O y S; y RF esta seleccionado entre hidrogeno, alquilo (C1-C7), carbociclilo, arilo y heteroarilo; en donde cada resto alquilo, cicloalquilo, alcoxi y cicloalcoxi en los grupos representados por R1 y R2 y cada heterociclo representado por NR1R2 tomados juntos esta opcionalmente sustituido con uno o mas sustituyentes seleccionados independientemente entre el grupo que consiste en alquilo (C1-C4), halo, -OH, alcoxi (C1-C4), alquiltio (C1-C4), alquilsulfinilo (C1-C4), alquilsulfonilo (C1-C4), alcoxi (C1-C4)-alquilo (C1-C4) y -N(R3)(R4); y cada resto arilo, ariloxi, ariltio, arilsufinilo y arilsulfonilo en los grupos representados por R1 y R2 y cada heteroarilo representado por NR1R2 tomados juntos estan opcionalmente sustituidos con uno o mas sustituyentes seleccionados independientemente entre el grupo que consiste en alquilo (C1-C4), halo, -OH, alcoxi (C1-C4), -Salquilo (C1-C4), -S(O)alquilo (C1-C4), -S(O)2alquilo (C1-C4), alcoxi (C1-C4)-alquilo (C1-C4), -N(R3)(R4); -CN, haloalquilo (C1-C4) y haloalcoxi (C1-C4), y cada uno de R3 y R4 esta seleccionado independientemente entre el grupo que consiste en -H y alquilo (C1-C4), en donde el alquilo (C1-C4) representado por R3 y R4 esta opcionalmente sustituido con uno o mas sustituyentes seleccionados independientemente entre el grupo que consiste en alquilo (C1-C4), halo, -OH, alcoxi (C1-C4) y alcoxi (C1-C4)-alquilo (C1-C4), y cada carbociclilo, arilo o heteroarilo en los grupos representados por X y RF esta opcionalmente e independientemente sustituido con uno o mas sustituyentes seleccionados independientemente entre halo, -alquilo (C1-C4), -OH, >=O, -O-alquilo (C1-C4), -alquil (C1-C4)-O-alquilo (C1-C4), -alquilo (C1-C4) halo sustituido, -O-alquilo (C1-C4) halo sustituido, -C(O)-alquilo (C1-C4), -C(O)-(alquilo (C1-C4) fluoro sustituido), - S(O)m-alquilo (C1-C4), -N(RG)(RG) y CN; en donde m es 1 o 2; cada RG es hidrogeno o alquilo (C1-C4), en donde cada alquilo en el grupo representado por RG esta opcionalmente e independientemente sustituido con uno o mas sustituyentes seleccionados independientemente entre -alquilo (C1-C4), cicloalquilo (C3-C6), halo, -OH, -O-alquilo (C1-C4) y alquil (C1-C4)-O-alquilo (C1-C4).

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
12
13
14
15
16
17
18
19
10
20
21
22
23
24
25
26
27
11
28
29
30
31
32
33 (referencia)
34
35
12
36
37
38
39
40
41
42
43
13
44
45
46
"Alquilo" se refiere un radical hidrocarburo alifático, monovalente de cadena lineal o ramificada que tiene el número especificado de átomos de carbono. Por lo tanto, "alquilo (C1-C7) " significa un radical que tiene de 1-7 átomos de carbono en una disposición lineal o ramificada. "alquilo (C1-C7)" incluye metilo, etilo, propilo, butilo, pentilo, hexilo y
5 heptilo. Las sustituciones adecuadas para un "alquilo sustituido" incluyen, pero sin limitación, -halógeno, -OH, alquilo (C1-C4), alcoxi (C1-C4), alquiltio (C1-C4), alquilsulfinilo (C1-C4), alquilsulfonilo (C1-C4), alcoxi (C1-C4)-alquilo (C1-C4) y N(R3)(R4), donde R3 y R4 son como se han descrito anteriormente.
"Cicloalquilo" se refiere a un radical hidrocarburo cíclico, alifático, saturado que tiene el número especificado de
10 átomos de carbono. El Cicloalquilo (C3-C6) incluye ciclopropilo, ciclobutilo, ciclopentilo y ciclohexilo. Los sustituyentes adecuados para a "cicloalquilo sustituido" incluyen halógeno, -OH, alquilo (C1-C4), alcoxi (C1-C4), alquiltio (C1-C4), alquilsulfinilo (C1-C4), alquil (C1-C4)-sulfonilo, alcoxi (C1-C4)-alquilo (C1-C4) y -N(R3)(R4), donde R3 y R4 son como se han descrito anteriormente.
15 "Heterociclo" se refiere a un anillo heterocíclico saturado o parcialmente insaturado de 4-12 miembros que contiene 1, 2 o 3 heteroátomos seleccionados independientemente entre N, O o S. Cuando un heteroátomo es S, éste puede estar opcionalmente mono o dioxigenado (es decir -S(O)-o -S(O)2-). El heterociclo puede ser monocíclico, bicíclico condensado, bicíclico puenteado o espiro bicíclico.
20 Los ejemplos de heterociclo monocíclico incluyen, pero sin limitación, azetidina, pirrolidina, piperidina, piperazina, hexahidropirimidina, tetrahidrofurano, tetrahidropirano, morfolina, tiomorfolina, 1,1-dioxido tiomorfolina, tetrahidro-2H1,2-tiazina, 1,1-dióxido de tetrahidro-2H-1,2-tiazina, isotiazolidina, 1,1-dioxido de isotiazolidina.
Un heterociclo bicíclico condensado tiene dos anillos que tienen dos átomos adyacentes en el anillo en común. El
25 primer anillo es un heterociclo monocíclico y el segundo anillo es un cicloalquilo, carbociclo parcialmente insaturado, fenilo, heteroarilo o un heterocilo monocíclico. Por ejemplo, el segundo anillo es un cicloalquilo (C3-C6), tal como ciclopropilo, ciclobutilo, ciclopentilo y ciclohexilo. Como alternativa, el segundo anillo es fenilo. Los ejemplos de heterociclos bicíclicos condensados incluyen, pero sin limitación, indolina, isoindolina, 2,3-dihidro-1Hbenzo[d]imidazol, 2,3-dihidrobenzo[d]oxazol, 2,3-dihidrobenzo[d]tiazol, octahidrobenzo[d]oxazol, octahidro-1H
30 benzo[d]imidazol, octahidrobenzo[d]tiazol, octahidrociclopenta[c]pirrol, 3-azabiciclo[3,1,0]hexano y 3azabiciclo[3,2,0]heptano.
Un heterociclo espiro bicíclico tiene dos anillos que tienen únicamente un átomo de anillo en común. El primer anillo es un heterociclo monocíclico y el segundo anillo es un cicloalquilo, carbociclo parcialmente insaturado o un
35 heterociclo bicíclico. Por ejemplo, el segundo anillo es un cicloalquilo (C3-C6). Los ejemplos de heterociclo espiro bicíclico incluyen, pero sin limitación, azaespiro[4,4]nonano, 7-azaespiro[4,4]nonano, azaesprio[4,5]decano, 8azaespiro[4,5]decano, azaespiro[5,5]undecano, 3-azaespiro[5,5]undecano y 3,9-diazaespiro[5,5]undecano.
Un heterociclo bicíclico puenteado tiene dos anillos que tienen tres o más átomos adyacentes en el anillo en común.
40 El primer anillo es un heterociclo monocíclico y el otro anillo es un cicloalquilo (tal como cicloalquilo (C3-C6)), carbociclo parcialmente insaturado o un heterociclo bicíclico. Los ejemplos de heterocíclicos bicíclicos puenteados incluyen, pero sin limitación, azabiciclo[3,3,1]nonano, 3-azabiciclo[3,3,1]nonano, azabiciclo[3,2,1]octano, 3azabiciclo[3,2,1]octano, 6-azabiciclo[3,2,1]octano y azabiciclo[2,2,2]octano, 2-azabiciclo[2,2,2]octano.
14
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
terapéutico puede ser cualquier agente que sea capaz de tratar, prevenir o reducir los síntomas de una enfermedad
o trastorno sensible a tetraciclina. Como alternativa, el otro agente terapéutico puede ser cualquier agente beneficioso para un paciente cuando se administra en combinación con el compuesto de tetraciclina en la presente invención.
5 Aunque la presente invención se ha mostrado y descrito particularmente con referencias a realizaciones de ejemplo de la misma, se entenderá por los expertos en la materia que pueden hacerse diversos cambios en la forma de los mismos sin alejarse del ámbito de la invención abarcada por las reivindicaciones adjuntas.
10 Ejemplos
Las siguientes abreviaturas y términos tienen los significados indicados:
Abreviatura/Término
Significado
Ac
acetilo
AIBN
2,2'-azobis(2-metilpropionitrilo)
ac.
acuoso
Bn
bencilo
salmuera
cloruro sódico acuoso saturado
Boc
terc-butoxi carbonilo o t-butoxi carbonilo
(Boc)2O
dicarbonato de di-terc-butilo
BBr3
tribromuro de boro
Bu
butilo
Cbz
benciloxicarbonilo
CH2Cl2
cloruro de metileno
CH3CN o ReCN
acetonitrilo
Cy
triciclohexilfosfina
dba
dibencilidenoacetona
DIBAL-H
hidruro de diisobutilaluminio
DIEA
N,N-diisopropiletilamina
DMAP
4-(dimetilamino)piridina
DME
1,2-dimetoxietano
DMF
N,N-dimetilformamida
DMPU
1,3-dimetil-3,4-5,6-tetrahidro-2(1 H)-pirimidona
DMSO
dimetilsulfóxido
EDC
N-(3-dimetilaminopropil)-N'-etilcarbodiimida
IEN
ionización por electronebulización
equiv.
equivalente
Et
etilo
Et2O
éter etílico
EtOAc
acetato de etilo
h
hora
HCl
ácido clorhídrico
KHPO4
hidrogenofosfato potásico
HPLC
cromatografía líquida de alto rendimiento
HOBt
1-hidroxibenzotriazol
i
iso
IBX
ácido 2-yodoxibenzoico
LDA
diisopropilamida de litio
LHMDS
bis(trimetilsilil)amida de litio
LTMP
2,2,6,6-tetrametilpiperiduro de litio
Me
metilo
MeOH
metanol
MeI
yoduro de metilo
min
minuto
Ms
metanosulfonilo
EM
espectro de masas
MTBE
metil terc-butil éter
PM
peso molecular
NaHCO3
bicarbonato sódico
NaOH
hidróxido sódico
Na2SO4
sulfato sódico
NBS
N-bromosuccinimida
24
imagen18
imagen19
imagen20
a la mezcla de reacción. La reacción se agitó de -78 ºC a 25 ºC durante 1 h, se detuvo con NH4Cl saturado y se extrajo con EtOAc. Los extractos de EtOAc combinados se secaron (Na2SO4) y se concentraron para producir el producto en bruto. La purificación por HPLC preparativa de fase inversa en un sistema Waters Autopurification usando una columna OBD Prep C18 de Sunfire [5 μm, 19 x 50 mm; caudal, 20 ml/min; Disolvente A: H2O con 5 HCO2H al 0,1 %; Disolvente B: CH3CN con HCO2H al 0,1 %; volumen de inyección: 4,0 ml (CH3CN); gradiente: B al 80→100 % durante 15 min; recogida de fracción dirigida a masas]. Las fracciones con el PM deseado, eluyendo a 6,3-8,0 min, se recogieron y se concentraron en un evaporador rotatorio a ta para retirar la mayoría del acetonitrilo. La solución, en su mayoría acuosa, resultante se extrajo con EtOAc. Los extractos de EtOAc combinados se secaron (Na2SO4) y se concentraron para dar 185 mg de 5 puro (35 %): RMN 1H (400 MHz, CDCl3) δ 15,67 (s, 1 H), 7,51
10 7,46 (m, 2 H), 7,39-7,29 (m, 3 H), 7,21 (dd, J= 8,9, 8,9 Hz, 1 H), 7,03 (dd, J =8,9, 4,0 Hz, 1 H), 5,34 (s, 2 H), 3,93 (d, J= 10,4 Hz, 1 H), 3,30-3,21 (m, 1 H), 3,10-3,00 (m, 1 H), 2,57-2,41 (m, 3 H), 2,48 (s, 6 H), 2,17-2,12 (m, 1 H), 1,53 (s, 9 H), 0,82 (s, 9 H), 0,26 (s, 3 H), 0,12 (s, 3 H); EM (IEN) m/z 735,45 (M+H).
Compuesto de Preparación 6 15
imagen21
Se añadieron HF acuoso (3 ml, 48 %) y TFA (4 μl) a una solución en CH3CN (7 ml) de 5 (210 mg, 0,29 mmol) en un tubo de polipropileno a 25 ºC. La reacción se agitó a 25 ºC durante 18 h. La mezcla resultante se vertió en una 20 solución acuosa de K2HPO4 (21 g, se disolvió en 150 ml de agua). La mezcla se extrajo con EtOAc. Los extractos de EtOAc combinados se secaron (Na2SO4) y se concentraron para producir 180 mg de 6 en bruto: RMN 1H (400 MHz, CDCl3) δ 14,64 (s, 1 H), 11,47 (s, 1 H), 7,49-7,45 (m, 2 H), 7,39-7,32 (m, 3 H), 7,14 (dd, J= 9,2, 8,8 Hz, 1 H), 6,77 (dd, J= 9,2, 4,3 Hz, 1 H), 5,36 (s, 2 H), 3,68 (d, J= 3,7 Hz, 1 H), 3,09 (dd, J= 15,6, 4,6 Hz, 1 H), 3,02-2,92 (m, 1 H), 2,84-2,79 (m, 1 H), 2,49 (s, 6 H), 2,34-2,22 (m, 1 H), 2,09-2,02 (m, 1 H), 1,55-1,44 (m, 1 H); EM (IEN) m/z 521,30
25 (M+H).
Compuesto de Preparación 7
imagen22
30 Se añadió paladio sobre carbono (35 mg, 10 % en peso) a una solución en MeOH/dioxano (4 ml/4 ml) de 6 en bruto (180 mg). La reacción se purgó con hidrógeno y se agitó en una atmósfera de H2 (globo) a 25 ºC durante 1 h. La mezcla de reacción se filtró a través de un lecho corto de Celite. El filtrado se concentró para producir el producto en bruto. La purificación por HPLC preparativa de fase inversa en un sistema Waters Autopurification usando una
35 columna 10 μ RP-1 100A de Phenomenex Polymerx [10 μm, 150 x 21,20 mm; caudal, 20 ml/min; Disolvente A: HCl 0,05 N/agua; Disolvente B: CH3CN; volumen de inyección: 4,0 ml (HCl 0,05 N/agua); gradiente: B al 0→100 % durante 15 min; recogida de fracción dirigida a masas]. Las fracciones con el PM deseado, eluyendo a 6,4-8,2 min, se recogieron y se deshidrataron por congelación para producir 51 mg del compuesto 7 (41 % en 2 etapas): RMN 1H (400 MHz, CD3OD) δ 7,26 (dd, J= 9,2, 9,2 Hz, 1 H), 6,80 (dd, J= 9,2, 4,3 Hz, 1 H), 4,09 (s a, 1 H), 3,14 (dd, J=
40 15,0, 4,6 Hz, 1 H), 3,04 (s, 3 H), 2,96 (s, 3 H), 3,09-2,91 (m, 2 H), 2,31-2,18 (m, 2 H), 1,68-1,56 (m, 1 H); EM (IEN) m/z 433,28 (M+H).
Compuesto de Preparación 8
imagen23
28
imagen24
varias veces con más cantidad de éter dietílico. Después, el lecho de Celite se eluyó con MeOH hasta que el eluyente se volvió incoloro. El eluyente de MeOH de color amarillo se recogió y se concentró a presión reducida para proporcionar 32 en bruto. Se realizó purificación por HPLC preparativa de fase inversa en un sistema Waters Autopurification, usando una columna 10 μ RP-1 100A de Phenomenex Polymem [10 μm, 150 x 21,20 mm, caudal, 5 20 ml/min; Disolvente A: HCl 0,05 N; Disolvente B: CH3CN; volumen de inyección: 2,0 ml (HCl 0,05 N/agua); gradiente: B 10→20 % durante 30 min, recogida de fracción dirigida a masas]. Las fracciones con el PM deseado, eluyendo a 10,8-12,5 min, se recogieron y se deshidrataron por congelación para producir 2,0 mg de 32 puro: RMN 1H (400 MHz, CD3OD) δ 8,18 (d, J= 11,0 Hz, 1 H), 4,41 -4,31 (m, 2 H), 4,32 (s, 2 H), 4,24-4,13 (m, 2), 4,08 (s a, 1 H), 3,18-2,86 (m, 3 H), 3,03 (s, 3 H), 2,95 (s, 3 H), 2,71-2,57 (m, 1 H), 2,54-2,42 (m, 1 H), 2,33-2,16 (m ,2 H), 1,69
10 1,57 (m, 1 H), EM (IEN) m/z 545,20 (M+H).
Los Compuestos 12-31 y los Compuestos 33-46 se prepararon de manera similar a los Compuestos 11 o 32, sustituyendo cloruro de 2-t-butilaminoacetilo en la síntesis del Compuesto 11 por el haluro de acilo adecuado, o azetidina por amina cíclica en la síntesis del Compuesto 32.
15 Compuesto 12
imagen25
20 RMN 1H (400 MHz, CD3OD) δ 8,23 (d, J= 11,2 Hz, 1 H), 4,08 (s, 3 H), 3,17-2,97 (m, 11 H), 2,31 (dd, J= 14,8, 14,8 Hz, 1 H), 2,24 (dd, J= 14,0, 5,2, 2,8 Hz, 1H), 1,79-1,72 (m, 2 H), 1,66 (ddd, J= 13,6, 13,6, 13,6 Hz, 1 H), 1,05 (t, J= 7,2 Hz, 3 H); EM (IEN) m/z 547,2 (M+H).
Compuesto de Referencia 13 25
imagen26
RMN 1H (400 MHz, CD3OD) δ 8,23 (d, J= 11,2 Hz, 1 H), 4,08 (s, 3 H), 3,16-2,97 (m, 11 H), 2,30 (dd, J= 14,8, 14,8 Hz, 1 H), 2,24 (ddd, J= 14,4, 5,2, 2,8 Hz, 1 H), 1,75-1,69 (m, 2 H), 1,66 (ddd, J= 13,6, 13,6, 13,6 Hz, 1 H), 1,49-1,41 30 (m, 2 H), 1,01 (t, J= 7,2 Hz, 3 H); EM (IEN) m/z 561,2 (M+H).
Compuesto 14
imagen27
35
RMN 1H (400 MHz, CD3OD) δ 8,21 (d, J = 11,2 Hz, 1 H), 4,08 (s, 1 H), 4,06 (s, 2 H), 3,16-2,96 (m, 11 H), 2,28 (dd, J = 14,8, 14,8 Hz, 1 H), 2,22 (ddd, J = 14,4, 5,2, 2,8 Hz, 1H), 1,77-1,71 (m, 2 H), 1,66 (ddd, J = 14,0, 14,0, 14,0 Hz, 1 H), 1,43-1,35 (m, 6 H),0,93 (t, J = 7,2 Hz, 3 H); EM (IEN) m/z 589,2 (M+H).
40
30
imagen28
imagen29
imagen30
imagen31
Compuesto 34
imagen32
RMN 1H (400 MHz, CD3OD) δ 8,22 (d, J= 11,0 Hz, 1H), 4,33 (s, 2H), 4,10 (s, 1H), 3,83-3,72 (m, 2H), 3,25-2,89 (m, 12H), 2,32-2,00 (m, 6H), 1,69-1,56 (m, 1H); EM (IEN) m/z 559,39 (M+H).
Compuesto 35
imagen33
10
RMN 1H (400 MHz, CD3OD) δ 8,25 (d, J= 11,0 Hz, 1H), 5,54-5,31 (m, 1H), 4,39-4,20 (m, 2H), 4,09-4,01 (m, 1H), 3,40-3,30 (m, 2H), 3,09-2,89 (m, 12H), 2,50-2,34 (m, 2H), 2,34-2,25 (m, 1H), 2,24-2,16 (m, 1H), 1,71-1,58 (m, 1H); EM (IEN) m/z 577,32 (M+H).
15 Compuesto 36
imagen34
20 RMN 1H (400 MHz, CD3OD) δ 8,23 (d, J= 10,4 Hz, 1H), 5,57-5,37 (m, 1H), 4,47-4,33 (m, 2H), 4,15-3,87 (m, 2H), 3,72-3,40 (m, 1H), 3,17-2,83 (m, 12H), 2,55-2,34 (m, 2H), 2,33-2,18 (m, 2H), 1,69-1,57 (m, 1H); EM (IEN) m/z 577,37 (M+H).
Compuesto 37 25
imagen35
RMN 1H (400 MHz, CD3OD) δ 8,28 (d, J= 10,7 Hz, 1H), 4,08 (s, 1H), 4,00-3,91 (m, 2H), 3,09-2,57 (m, 18H), 3,263,18 (m, 3H), 2,49-2,34 (m, 2H), 2,35-2,06 (m, 2H), 1,72-1,59 (m, 1H); EM (IEN) m/z 602,37 (M+H).
Compuesto 38
imagen36
35
imagen37
imagen38
imagen39
imagen40
Compuesto 58
imagen41
5 RMN 1H (400 MHz, CD3OD) δ 8,24 (d, J= 10,8 Hz, 1 H), 4,48 (s, 2 H), 4,12 (s, 1 H), 4,10-4,07 (m, 2 H), 3,93-3,86 (m, 2 H), 3,19-2,90 (m, 9 H), 2,79-2,67 (m, 2 H), 2,37-2,21 (m, 2 H), 1,59-1,51 (m, 1 H); EM (IEN) m/z 595,0 (M+H).
Ejemplo 2. Síntesis de Compuestos de la Fórmula Estructural (I), en la que R1 y R2 tomados junto con el nitró nitrógeno al que están enlazados forman un heteroarilo monocíclico o bicíclico.
10
imagen42
Los siguientes compuestos se prepararon de acuerdo con el Esquema 2. 15 Compuesto de Preparación 2-1
imagen43
En un matraz de fondo redondo de 250 ml se añadió el compuesto 3 (14,47 g, 56,30 mmol, 1,0 equiv, en bruto), 20 bromuro de tetrabutilamonio (0,90 g, 2,80 mmol, 0,05 equiv.), 1,2-dicloroetano (60 ml) y agua (60 ml). La bi-fase transparente se enfrió en un baño de agua a 20 ºC. Se añadió ácido cítrico (7,2 ml, 70 % en peso, 112,60 mmol, 2,0
40
imagen44
imagen45
imagen46
imagen47
imagen48
imagen49
imagen50
imagen51
imagen52
imagen53
imagen54
imagen55
imagen56
imagen57
imagen58
imagen59
imagen60
imagen61
imagen62
imagen63
imagen64
imagen65
imagen66
imagen67
imagen68
imagen69
imagen70
imagen71
imagen72
imagen73
imagen74
imagen75
imagen76
imagen77
imagen78
imagen79
imagen80
imagen81
imagen82
imagen83
imagen84
Punto del Pocillo
1 2 3 4 5 6
Factor de Dilución
102 103 104 105 106 107
Cepas bacterianas
Se examinaron quince cepas bacterianas, enumeradas a continuación, en ensayos de concentración inhibidora mínima (MIC).
ID
Organismo Fuente Resistencia Comentarios Rx Gram
SA100
S. aureus ATCC 13709 MSSA Cepa Smith (modelo animal) positivo
SA101
S. aureus ATCC 29213 MSSA control positivo
SA158
S. aureus MR, SK75 resistente a tet: tetK (salida) positivo
SA161
S. aureus Micromyx, LLC resistente a tet: tet(M) protección ribosómica positivo
EF103
E. faecalis ATCC 29212 intermedio de tet/resistente – mecanismo no especificado control positivo
EF159
E. faecalis MR, DS160 resistente a tet:tetM (protección de rib) cip-R, ery-1 positivo
SP106
S. pneumoniae ATCC 49619 wt control positivo
SP160
S. pneumoniae MR, 54 resistente a tet:tet M (protección de rib) pen-R, ery-R positivo
EC107
E. coli ATCC 25922 wt control negativo
EC155
E. coli MR, 10 resistente a tet:tetA (salida) negativo
KP109
K. pneumoniae ATCC 13883 wt negativo
KP153
K. pneumoniae MR, 1 resistente a tet: tetA (salida) cip-R, gen-R negativo
EC108
E. cloacae ATCC 13047 wt negativo
AB110
A. baumanii ATCC 19606 wt negativo
PA111
P. aeruginosa ATCC 27853 wt control negativo
MSSA = S. aureus susceptible a meticilina wt = natural ATCC = Colección Americana de Cultivos Tipo MR = Marilyn Roberts, Universidad de Washington tet = tetraciclina cip = ciprofloxacina R = resistente gen = gentamicina ery = eritromicina pen = penicilina
Resultados Se proporcionan los valores de concentración inhibidora mínima (MIC) para los compuestos en las Tablas 1a, 1b, 2a, 10 2by3. Tabla 1a
ID del compuesto
MIC (µg/ml)
SA101
SA100 SA161 SA158 EF103 EF159 SP106 S0160
11
0,125 0,25 0,25 0,0625 0,0625 0,125 ≤0,0156 ≤0,0156
12
≤0,0156 ≤0,0156 0,125 0,5 ≤0,0156 0,0625 ≤0,0156 ≤0,0156
13
≤0,0156 ≤0,0156 0,0625 0,25 ≤0,0156 0,0625 ≤0,0156 ≤0,0156
14
0,5 0,25 0,5 0,25 0,125 0,25 0,03 0,125
15
0,5 0,5 0,5 0,25 0,5 0,5 0,016 0,016
16
0,125 0,25 0,25 0,5 0,0625 0,0625 ≤0,0156 ≤0,0156
17
0,25 0,5 1 2 0,25 1 0,0625 0,0625
18
0,0625 ≤0,0156 0,0625 0,125 ≤0,0156 0,0313 ≤0,0156 ≤0,0156
19
0,125 0,25 0,25 0,25 ≤0,0156 0,125 ≤0,0158 ≤0,0156
20
≤0,0156 0,25 0,25 0,5 ≤0,0156 0,0625 ≤0,0156 ≤0,0156
21
0,25 0,25 0,5 4 0,125 1 ≤0,0156 0,0625
22
1 1 2 4 2 4 0,5 1
23
≤0,0156 0,5 0,125 0,25 ≤0,0156 0,0313 ≤0,0156 ≤0,0156
24
0,25 0,25 0,125 0,125 ≤0,0156 ≤0,0156 ≤0,0156 ≤0,0156
25
0,125 0,125 0,125 0,0313 ≤0,0156 0,0625 ≤0,0156 ≤0,0156
82
imagen85
imagen86
imagen87
imagen88
imagen89
87
imagen90
imagen91
imagen92
imagen93
imagen94
imagen95
imagen96
imagen97
imagen98
imagen99

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
ES15180611.4T 2008-08-08 2009-08-07 Compuestos de tetraciclina sustituidos con C7-fluoro Active ES2655911T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18830708P 2008-08-08 2008-08-08
US188307P 2008-08-08

Publications (1)

Publication Number Publication Date
ES2655911T3 true ES2655911T3 (es) 2018-02-22

Family

ID=41110902

Family Applications (3)

Application Number Title Priority Date Filing Date
ES13172357.9T Active ES2558512T3 (es) 2008-08-08 2009-08-07 Compuestos de tetraciclina sustituida con C7-fluoro
ES09791290T Active ES2430254T3 (es) 2008-08-08 2009-08-07 Compuestos de tetraciclina sustituidos con c7-fluoro
ES15180611.4T Active ES2655911T3 (es) 2008-08-08 2009-08-07 Compuestos de tetraciclina sustituidos con C7-fluoro

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES13172357.9T Active ES2558512T3 (es) 2008-08-08 2009-08-07 Compuestos de tetraciclina sustituida con C7-fluoro
ES09791290T Active ES2430254T3 (es) 2008-08-08 2009-08-07 Compuestos de tetraciclina sustituidos con c7-fluoro

Country Status (32)

Country Link
US (9) US8906887B2 (es)
EP (3) EP2682387B1 (es)
JP (3) JP5496202B2 (es)
KR (3) KR101746795B1 (es)
CN (3) CN102177134B (es)
AR (3) AR072990A1 (es)
AU (1) AU2009279473B2 (es)
BR (1) BRPI0916985B1 (es)
CA (1) CA2732883C (es)
CO (1) CO6351777A2 (es)
CY (3) CY1114689T1 (es)
DK (2) DK2682387T3 (es)
ES (3) ES2558512T3 (es)
FR (1) FR19C1012I2 (es)
HK (3) HK1155150A1 (es)
HR (2) HRP20130928T1 (es)
HU (2) HUE026562T2 (es)
IL (3) IL211120A (es)
LT (1) LTC2323972I2 (es)
LU (1) LUC00107I2 (es)
MX (2) MX2011001367A (es)
NL (1) NL300971I2 (es)
NO (1) NO2019010I1 (es)
NZ (3) NZ624272A (es)
PL (3) PL3000805T3 (es)
PT (2) PT2682387E (es)
RS (2) RS54485B1 (es)
SG (1) SG10201806714PA (es)
SI (2) SI2323972T1 (es)
SM (1) SMT201600045B (es)
TW (3) TWI453183B (es)
WO (1) WO2010017470A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201806714PA (en) 2008-08-08 2018-09-27 Tetraphase Pharmaceuticals Inc C7-fluoro substituted tetracycline compounds
CA2761241C (en) 2009-05-08 2018-02-27 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
CA2772386C (en) 2009-08-28 2017-09-19 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
WO2012021829A1 (en) * 2010-08-12 2012-02-16 Tetraphase Pharmaceuticals, Inc. Methods of treating bacterial infections
AR082633A1 (es) * 2010-08-12 2012-12-19 Tetraphase Pharmaceuticals Inc Analogos de tetraciclina
WO2012065028A2 (en) 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
BR112015004523B1 (pt) 2012-08-31 2020-08-04 Tetraphase Pharmaceuticals, Inc Compostos de tetraciclina, composições farmacêuticas e seus usos
CN104230960B (zh) * 2013-06-06 2017-02-15 山东轩竹医药科技有限公司 四并环类间变性淋巴瘤激酶抑制剂
MA40836A (fr) * 2014-10-23 2017-08-29 Tetraphase Pharmaceuticals Inc Procédures de semi-synthèse
WO2017097891A1 (en) 2015-12-10 2017-06-15 Sandoz Ag Crystalline eravacycline
PT3390358T (pt) 2016-01-22 2020-11-09 Sandoz Ag Bis-cloridrato de eravaciclina cristalino
RU2018140463A (ru) * 2016-05-02 2020-06-03 Паратек Фармасьютикалс, Инк. 9-аминометилминоциклиновые соединения и способы их применения для лечения инфекций мочевых путей (имп)
CN107759503A (zh) * 2016-08-16 2018-03-06 四川科伦博泰生物医药股份有限公司 一种四环素衍生物及其用途
CA3034891A1 (en) * 2016-08-30 2018-03-08 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds and methods of treatment
SG11201903327PA (en) 2016-10-19 2019-05-30 Tetraphase Pharmaceuticals Inc Crystalline forms of eravacycline
RU2019113715A (ru) 2016-11-01 2020-12-03 Паратек Фармасьютикалс, Инк. 9-аминометилминоциклиновые соединения и их применение для лечениия внебольничной бактериальной пневмонии(вбп)
US20210395198A1 (en) 2018-11-09 2021-12-23 Tetraphase Pharmaceuticals, Inc. Polymorphic forms of a compound and uses thereof
WO2023233397A1 (en) * 2022-05-29 2023-12-07 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Eravacycline for treating cancer

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB935384A (en) * 1959-03-30 1963-08-28 Pfizer & Co C Tetracycline derivatives and preparation thereof
US3338963A (en) * 1960-10-28 1967-08-29 American Cyanamid Co Tetracycline compounds
GB1034933A (en) 1962-10-29 1966-07-06 American Cyanamid Co 4-demethylamino-4-substituted amino 6-demethyl tetracyclines
US3304227A (en) 1965-07-15 1967-02-14 Loyal E Loveless Antibiotic-containing animal feed
US3433709A (en) * 1965-12-07 1969-03-18 American Cyanamid Co Biological transformation of alpha-6-deoxytetracyclines to tetracyclines
US4666897A (en) 1983-12-29 1987-05-19 Research Foundation Of State University Inhibition of mammalian collagenolytic enzymes by tetracyclines
US4935412A (en) 1983-12-29 1990-06-19 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4925833A (en) 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
USRE34656E (en) 1983-12-29 1994-07-05 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency
US4704383A (en) 1983-12-29 1987-11-03 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US5308839A (en) 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
JP3016587B2 (ja) 1989-12-04 2000-03-06 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 非ステロイド抗炎症剤及びテトラサイクリンの配合
US5770588A (en) 1991-02-11 1998-06-23 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions of the prevention and treatment of root caries
US5231017A (en) 1991-05-17 1993-07-27 Solvay Enzymes, Inc. Process for producing ethanol
US5494903A (en) * 1991-10-04 1996-02-27 American Cyanamid Company 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
SG52361A1 (en) * 1991-10-04 1998-09-28 American Cyanamid Co Novel 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
USRE40183E1 (en) 1991-10-04 2008-03-25 Wyeth Holdings Corporation 7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US5258371A (en) 1992-05-29 1993-11-02 Kuraray Co., Ltd. Method to reduce connective tissue destruction
US6043225A (en) 1992-06-12 2000-03-28 Board Of Regents Of The University Of Washington Diagnosis and treatment of arterial chlamydial granuloma
US5420272A (en) * 1992-08-13 1995-05-30 American Cyanamid Company 7-(substituted)-8-(substituted)-9-](substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
SG47520A1 (en) 1992-08-13 1998-04-17 American Cyanamid Co New method for the production of 9-amino-6-demethyl-6-deoxytetracycline
US5284963A (en) * 1992-08-13 1994-02-08 American Cyanamid Company Method of producing 7-(substituted)-9-[(substituted glycyl)-amidol]-6-demethyl-6-deoxytetra-cyclines
US5328902A (en) * 1992-08-13 1994-07-12 American Cyanamid Co. 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
DK0599397T3 (da) 1992-11-17 1996-09-16 Univ New York State Res Found Tetracycliner, herunder non-mikrobielle, kemisk-modificerede tetracycliner, inhiberer overdreven collagentværbinding ved diabetes
US5523297A (en) 1993-03-02 1996-06-04 The Research Foundation Of State University Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US6043231A (en) 1993-03-02 2000-03-28 The Research Foundation Of State Univ. Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5371076A (en) * 1993-04-02 1994-12-06 American Cyanamid Company 9-[(substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines
US5668122A (en) 1993-07-28 1997-09-16 Fife; Rose S. Method to treat cancer with tetracyclines
CA2183565A1 (en) 1994-02-17 1995-08-24 Wei-Guo Su 9-(substituted amino)-alpha-6-deoxy-5-oxy tetracycline derivatives, their preparation and their use as antibiotics
US5574026A (en) 1994-12-13 1996-11-12 American Cyanamid Company Methods for inhibiting angiogenesis proliferation of endothelial or tumor cells and tumor growth
US5843925A (en) 1994-12-13 1998-12-01 American Cyanamid Company Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US5495301A (en) * 1994-12-27 1996-02-27 Zenith Electronics Corporation Three wire pillow speaker with full television remote control functions
US5834449A (en) 1996-06-13 1998-11-10 The Research Foundation Of State University Of New York Treatment of aortic and vascular aneurysms with tetracycline compounds
US5827840A (en) 1996-08-01 1998-10-27 The Research Foundation Of State University Of New York Promotion of wound healing by chemically-modified tetracyclines
US5789395A (en) 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5919774A (en) 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
US5837696A (en) 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
US5773430A (en) 1997-03-13 1998-06-30 Research Foundation Of State University Of New York Serine proteinase inhibitory activity by hydrophobic tetracycline
US5929055A (en) 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus
US6277061B1 (en) 1998-03-31 2001-08-21 The Research Foundation Of State University Of New York Method of inhibiting membrane-type matrix metalloproteinase
US6015804A (en) 1998-09-11 2000-01-18 The Research Foundation Of State University Of New York Method of using tetracycline compounds to enhance interleukin-10 production
US5977091A (en) 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
US6914057B1 (en) * 1998-09-28 2005-07-05 The Research Foundation Of State University Of New York Inhibitor of cataract formation
US5998390A (en) 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
KR20010073190A (ko) 1998-09-28 2001-07-31 제임스 알. 데니히 백내장 형성 억제제
US6231894B1 (en) 1999-10-21 2001-05-15 Duke University Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase
AU2000257445A1 (en) 2000-06-16 2002-01-02 Trustees Of Tufts College 7-n-substituted phenyl tetracycline compounds
US6624168B2 (en) 2000-07-07 2003-09-23 Trustees Of Tufts College 7,8 and 9-substituted tetracycline compounds
ATE544745T1 (de) * 2000-07-07 2012-02-15 Tufts College 9-substituierte minocyclinverbindungen
US7045507B2 (en) * 2001-03-14 2006-05-16 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds as synergistic antifungal agents
US6841546B2 (en) * 2001-03-14 2005-01-11 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds as antifungal agents
CA2444899C (en) 2001-04-24 2011-06-21 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
US8088820B2 (en) * 2001-04-24 2012-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
EP2332548A1 (en) 2001-07-13 2011-06-15 Paratek Pharmaceuticals, Inc. Tetracyclines for the treatment of stroke
US20060194773A1 (en) * 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
EP1482926A4 (en) * 2002-03-08 2006-04-12 Paratek Pharm Innc AMINO METHYL SUBSTITUTED TETRACYCLINE COMPOUNDS
KR101025400B1 (ko) 2002-03-21 2011-03-28 파라테크 파마슈티컬스, 인크. 치환된 테트라시클린 화합물
AU2003261161B2 (en) 2002-07-12 2009-09-10 Paratek Pharmaceuticals, Inc 3, 10, and 12a substituted tetracycline compounds
EP2277504A1 (en) 2002-10-24 2011-01-26 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
WO2004038000A2 (en) * 2002-10-24 2004-05-06 Paratek Pharmaceuticals, Inc. Methods of using substituted tetracycline compounds to modulate rna
EP2319829A1 (en) * 2003-07-09 2011-05-11 Paratek Pharmaceuticals, Inc. 9-substituted tetracycline compounds
SI1753713T1 (sl) 2004-05-21 2017-01-31 President And Fellows Of Harvard College Sinteza tetraciklinov in njihovih analogov
CA2585418A1 (en) 2004-10-25 2006-05-04 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines and methods of use thereof
EP1848685A1 (en) 2005-02-04 2007-10-31 Paratek Pharmaceuticals, Inc. 11a, 12-derivatives of tetracycline compounds
BRPI0607353A2 (pt) * 2005-02-15 2009-09-01 Wyeth Corp composto de fórmula (i); composição farmacêutica; uso do composto para o tratamento ou controle de infecções bacterianas em animais de sangue quente; processo para a preparação de tetraciclinas 9-(n-substituìdas-n-substituìdas-glicil) de fórmulas 5; 7; 10; e tetraciclina 9-(n-substituìda-n-substituìda glicil) de fómulas 5; 7; 10
AU2006272698B2 (en) * 2005-07-21 2012-11-01 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
AU2007208214B2 (en) 2006-01-24 2013-02-14 Paratek Pharmaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
WO2007117639A2 (en) 2006-04-07 2007-10-18 The President And Fellows Of Harvard College Synthesis of tetracyclines and analogues thereof
EP2537934A3 (en) 2006-05-15 2013-04-10 Paratek Pharmaceuticals, Inc. Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
EP2479169B1 (en) 2006-10-11 2014-12-03 President and Fellows of Harvard College Synthesis of Enone Intermediate
US8440646B1 (en) 2006-10-11 2013-05-14 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of Bacillus anthracis infections
WO2008127722A1 (en) 2007-04-12 2008-10-23 Paratek Pharmaceuticals, Inc. Methods for treating spinal muscular atrophy using tetracycline compounds
WO2009032326A1 (en) * 2007-09-07 2009-03-12 Dr. Reddy's Laboratories Ltd. New tetracycline derivatives as antiinfective agents
AU2009236631A1 (en) 2008-04-14 2009-10-22 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
SG10201806714PA (en) * 2008-08-08 2018-09-27 Tetraphase Pharmaceuticals Inc C7-fluoro substituted tetracycline compounds
US9073829B2 (en) 2009-04-30 2015-07-07 President And Fellows Of Harvard College Synthesis of tetracyclines and intermediates thereto
CA2761241C (en) 2009-05-08 2018-02-27 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
ES2440000T3 (es) 2009-05-08 2014-01-27 Tetraphase Pharmaceuticals, Inc. Compuestos de 8-aza-tetraciclina
CA2772386C (en) * 2009-08-28 2017-09-19 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
AR082633A1 (es) 2010-08-12 2012-12-19 Tetraphase Pharmaceuticals Inc Analogos de tetraciclina
WO2012047907A1 (en) 2010-10-04 2012-04-12 President And Fellows Of Harvard College Synthesis of c5-substituted tetracyclines, uses thereof, and intermediates thereto
BR112015004523B1 (pt) 2012-08-31 2020-08-04 Tetraphase Pharmaceuticals, Inc Compostos de tetraciclina, composições farmacêuticas e seus usos

Also Published As

Publication number Publication date
LUC00107I2 (es) 2019-12-27
HUE026562T2 (hu) 2016-06-28
HK1193412A1 (zh) 2014-09-19
FR19C1012I1 (es) 2019-04-19
JP5690957B2 (ja) 2015-03-25
CN103936645B (zh) 2016-03-09
AR112533A2 (es) 2019-11-06
HRP20151368T1 (hr) 2016-01-15
EP2323972A1 (en) 2011-05-25
HK1155150A1 (en) 2012-05-11
SI2682387T1 (sl) 2016-01-29
US20170275244A1 (en) 2017-09-28
TW201538483A (zh) 2015-10-16
US8796245B2 (en) 2014-08-05
CY2019011I2 (el) 2019-11-27
PT2682387E (pt) 2016-02-03
TWI453183B (zh) 2014-09-21
EP2682387B1 (en) 2015-10-07
PL3000805T3 (pl) 2018-04-30
CY1114689T1 (el) 2016-12-14
EP2323972B1 (en) 2013-07-03
KR101856178B1 (ko) 2018-05-10
SMT201600045B (it) 2016-02-25
JP2011530534A (ja) 2011-12-22
DK2323972T3 (da) 2013-10-07
TWI508934B (zh) 2015-11-21
KR20110058800A (ko) 2011-06-01
WO2010017470A1 (en) 2010-02-11
BRPI0916985A2 (pt) 2018-02-14
SI2323972T1 (sl) 2013-11-29
AU2009279473A1 (en) 2010-02-11
NZ591051A (en) 2012-12-21
US8501716B2 (en) 2013-08-06
NZ624272A (en) 2015-10-30
BRPI0916985B1 (pt) 2021-06-22
PL2682387T3 (pl) 2016-03-31
PL2323972T3 (pl) 2014-01-31
TW201016646A (en) 2010-05-01
ES2558512T3 (es) 2016-02-04
NZ603568A (en) 2014-05-30
MX2011001367A (es) 2011-06-28
TWI585077B (zh) 2017-06-01
KR20160052813A (ko) 2016-05-12
LUC00107I1 (es) 2019-03-14
HRP20130928T1 (hr) 2013-11-22
US20130109657A1 (en) 2013-05-02
US20100105671A1 (en) 2010-04-29
US20190002398A1 (en) 2019-01-03
IL211120A (en) 2014-09-30
KR101679023B1 (ko) 2016-11-24
LTC2323972I2 (lt) 2019-11-25
IL231954A0 (en) 2014-05-28
CN103936645A (zh) 2014-07-23
NO2019010I1 (no) 2019-03-01
AR112532A2 (es) 2019-11-06
JP6041911B2 (ja) 2016-12-14
AU2009279473B2 (en) 2012-12-13
US20210122709A1 (en) 2021-04-29
EP2682387A3 (en) 2014-06-18
CY1117085T1 (el) 2017-04-05
KR20170018483A (ko) 2017-02-17
DK2682387T3 (en) 2016-01-04
CA2732883A1 (en) 2010-02-11
SG10201806714PA (en) 2018-09-27
US20230122651A1 (en) 2023-04-20
US20120302527A1 (en) 2012-11-29
JP5496202B2 (ja) 2014-05-21
IL231954A (en) 2017-12-31
CN105367440A (zh) 2016-03-02
CY2019011I1 (el) 2019-11-27
PT2323972E (pt) 2013-10-09
FR19C1012I2 (fr) 2019-12-13
EP3000805B1 (en) 2017-10-18
EP3000805A1 (en) 2016-03-30
ES2430254T3 (es) 2013-11-19
RS53003B (en) 2014-04-30
US20150274643A1 (en) 2015-10-01
TW201429930A (zh) 2014-08-01
LTPA2019009I1 (lt) 2019-04-10
JP2015120723A (ja) 2015-07-02
JP2014148509A (ja) 2014-08-21
IL231955B (en) 2018-01-31
NL300971I2 (nl) 2019-04-11
IL211120A0 (en) 2011-04-28
US8906887B2 (en) 2014-12-09
US20200055813A1 (en) 2020-02-20
AR072990A1 (es) 2010-10-06
CN102177134A (zh) 2011-09-07
CO6351777A2 (es) 2011-12-20
MX358961B (es) 2018-09-10
RS54485B1 (en) 2016-06-30
KR101746795B1 (ko) 2017-06-13
EP2682387A2 (en) 2014-01-08
IL231955A0 (en) 2014-05-28
CA2732883C (en) 2018-03-06
HK1222840A1 (zh) 2017-07-14
HUS1900016I1 (hu) 2019-04-29
CN102177134B (zh) 2014-04-16

Similar Documents

Publication Publication Date Title
ES2655911T3 (es) Compuestos de tetraciclina sustituidos con C7-fluoro
US11547704B2 (en) Chemical compounds
JP7502337B2 (ja) Ｋｒａｓ ｇ１２ｃインヒビター及びその使用
AU2013288265B2 (en) Tetrahydroquinazolinone derivatives as PARP inhibitors
WO2017212423A1 (en) Chemcical compounds
PE20212023A1 (es) Compuestos, composiciones y metodos
AR076765A1 (es) Compuestos antivirales
WO2019008506A1 (en) N- (3- (2- (4-CHLOROPHENOXY) ACETAMIDO) BICYCLO [1.1.1] PENTAN-1-YL) -2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES
EP3039025A1 (en) Antimicrobial compounds and methods of making and using the same
AU2017292522A1 (en) Combination comprising EP4 antagonist and immune checkpoint inhibitor
ES2678770T3 (es) Derivados de amida de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor
US20200140383A1 (en) 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
ES2413704T3 (es) Procedimiento de fabricación de derivados de ácido neuramínico
SG10201907667RA (en) Morphinan derivative
EP3617204A1 (en) Indoleamine 2,3-dioxygenase inhibitor and application
ES2566755T3 (es) Inhibidores de FXa con amidoxima cíclica o amidrazona cíclica como subunidad P4, procedimientos para sus preparaciones, y composiciones farmacéuticas y derivados de los mismos
CO2022004391A2 (es) Derivados de 5-oxa-2–azaespiro[3.4]octano como agonistas de m4
ES2354550A1 (es) Biblioteca de n-(1-fenil-2-oxo-3-piperidil)sulfonamidas para el descubrimiento de fármacos.
CA3015098A1 (en) New toxin and method for preparing intermediate thereof
ES2794801T3 (es) Compuestos oxaazaespíricos con actividad contra el dolor
AR119092A1 (es) Compuestos tricíclicos y su uso
NZ789384A (en) Combination comprising EP4 antagonist and immune checkpoint inhibitor
NZ733899A (en) [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
AR056683A1 (es) INHIBIDORES DE PROTEASA DEL VIH, COMPOSICIoN FARMACÉUTICA Y USO DEL COMPUESTO PARA PREPARAR UN MEDICAMENTO